Erasca (ERAS) is back in focus after reporting second quarter 2026 results that showed a wider net loss, alongside the appointment of veteran oncology leader Charles S. Fuchs as president of research and development.

Erasca’s recent earnings release, shelf registration filing of up to US$112.344 million and the ongoing securities class action have all landed while the stock trades at US$18.10, with a 90 day share price return of 55.97% and a year to date share price return of 404.18%. This contrasts with a three year total shareholder return of 5.8x and a five year total shareholder return that is down 17.54%, which suggests that momentum has picked up sharply in the shorter term after a mixed longer run.

If you are looking beyond Erasca and want to see what else is moving in related areas of the market, now could be a good time to review 42 healthcare AI stocks.

Erasca now combines a focused oncology pipeline, a wider recent loss and a sharply higher share price. The question for you is whether that mix adds up to a stock that is already expensive or still reasonable.

Preferred Price to Book Multiple of 17.5x for Erasca: Is it justified?

On recent figures, Erasca trades on a price to book ratio of 17.5x, compared with around 7.5x for peers and 2.5x for the broader US Biotechs industry. That gap means the stock carries a much richer valuation than many investors might usually see in this sector.

The P/B multiple compares Erasca’s market value to its book value, which is essentially its net assets on the balance sheet. For early stage biotechs with minimal revenue and ongoing losses, investors often lean on P/B because traditional profit based measures like P/E are not meaningful when a company is unprofitable.

In this case, Erasca is currently loss making, reports no meaningful revenue and is forecast to remain unprofitable over the next three years. The P/B multiple therefore suggests the market is paying a high premium over the company’s net asset base while there is still no clear line of sight to profitability according to the available forecasts.

Compared with both similar sized peers at 7.5x and the wider US Biotechs group at 2.5x, Erasca’s 17.5x P/B ratio is significantly higher. That scale of difference indicates the stock is priced well above the sector’s typical range for asset backing, even before any consideration of future earnings or cash flows.

Result: Price-to-book of 17.5x (OVERVALUED)

However, Erasca’s widened net loss of US$287.223 million and the ongoing securities class action could quickly challenge sentiment if expectations shift or funding conditions tighten.

Next Steps

If this mix of optimism and concern around Erasca feels finely balanced, now is the time to review the details and decide where you stand using the 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond Erasca?

Do not stop your research with Erasca. Use these focused screeners to spot other stocks that match the kind of opportunities you want to back next.

• Target potential mispricings by reviewing companies flagged in the 50 high quality undervalued stocks.
• Strengthen your income approach by checking which stocks qualify as 11 dividend fortresses.
• Prioritise resilience by focusing on companies highlighted in the 79 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.